M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Already a member? Log in here
Preparing for or Considering Sale: The Anatomy of a Deal and Maximizing Your Opportunity
This panel will help laboratory owners make decisions now to be better positioned in the future for a potential sale.
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
Pfizer Acquires Lucira Health for $36.4 Million in Bankruptcy Auction
Lucira has fallen on hard times since it secured the first FDA EUA for an at-home COVID-19 test in November 2020.
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Already a member? Log in here